Delivery Order SPE2DB24D2010-SPE2DB25FAAYX
- Not listed
- The Defense Logistics Agency awarded a $7,891.76 delivery order to AmerisourceBergen Drug Corp for Otezla 30 mg tablets (60-count) on June 20, 2025, with completion scheduled for June 23, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $18,874.86 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) on August 20, 2025, with a completion date of August 21, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of...
- The Defense Logistics Agency awarded a $1,311.62 delivery order to AmerisourceBergen Drug Corp for 60 tablets of Otezla 30 mg on August 13, 2025, with an ultimate completion date of August 14, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and is being performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The delivery order represents a child contract action under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) under a firm fixed-price arrangement. The award, issued on September 23, 2025, carries a ceiling value of $16,955.15 with an ultimate completion date of September 24, 2025. This non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $1 billion...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $35,330.15 by the Defense Logistics Agency (DLA) on September 17, 2025, for the supply of Otezla 30 mg tablets (60-count units). This firm fixed-price, competitively awarded contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The contract carries no set-aside...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $45,214.89 on September 11, 2025, for the supply of Otezla 30 mg tablets (60-count units). This firm fixed-price, competitively awarded contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical products will be delivered to the company's distribution facility...
- The Defense Logistics Agency awarded a delivery order valued at $31,478.88 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) on September 23, 2025, with completion scheduled for September 24, 2025. This non-set-aside contract represents a firm fixed price delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive $999.99 billion global pharmaceutical support vehicle running through...
- The Defense Logistics Agency awarded a delivery order valued at $12,445.76 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The...
- The Defense Logistics Agency awarded a $36,477.84 delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Otezla 30 mg tablets (60-count units). The contract is a firm fixed price delivery order with an ultimate completion date of July 30, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This award was competitively awarded with no set-aside designation. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Otezla 30 mg tablets (60-count units) under a firm fixed-price contract valued at $21,053.19. The contract, with an ultimate completion date of August 28, 2025, represents a non-set-aside competitive award and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued against...
- SPE2DB24D2010Indefinite Delivery Contract
- SPE2DB24D2010-SPE2DB25FAAYXDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $36,319.73 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count packages) on August 26, 2025, with completion scheduled for August 27, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract action under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion comprehensive pharmaceutical supply vehicle running through December 2026 that enables the company to furnish pharmaceutical products and medical supplies to support military healthcare programs globally. As a major pharmaceutical distributor and critical federal vendor, AmerisourceBergen Drug Corp fulfills extensive medical procurement requirements across the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's federal contract portfolio demonstrates consistent capability in delivering specialty medications, brand-name and generic pharmaceuticals, vaccines, and medical supplies across multiple therapeutic domains through competitively awarded arrangements with DLA. This delivery order for Otezla, a prescription medication used in the treatment of psoriatic arthritis and other autoimmune conditions, reflects the company's ongoing role as a primary supplier of pharmaceutical commodities to support military and federal healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $36.3k | 8/26/25 |